With 1.32 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.83 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.81 whereas the lowest price it dropped to was $3.6. The 52-week range on ATYR shows that it touched its highest point at $4.22 and its lowest point at $1.42 during that stretch. It currently has a 1-year price target of $20.00. Beta for the stock currently stands at 1.00.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATYR was down-trending over the past week, with a drop of -8.63%, but this was up by 9.42% over a month. Three-month performance surged to 15.38% while six-month performance rose 98.90%. The stock gained 82.74% in the past year, while it has lost -0.55% so far this year. A look at the trailing 12-month EPS for ATYR yields -0.94 with Next year EPS estimates of -0.81. For the next quarter, that number is -0.23. This implies an EPS growth rate of 2.84% for this year and 11.19% for next year. EPS is expected to grow by 13.72% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 43.36%.
Float and Shares Shorts:
At present, 83.94 million ATYR shares are outstanding with a float of 81.93 million shares on hand for trading. On 2025-01-31, short shares totaled 3.82 million, which was 455.00003 higher than short shares on 1735603200. In addition to Dr. Sanjay S. Shukla M.D., M.S. as the firm’s President, CEO & Director, Ms. Jill M. Broadfoot CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.64439005 of ATYR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, ATYR reported revenue of $0.0 and operating income of -$18143000.0. The EBITDA in the recently reported quarter was -$17755000.0 and diluted EPS was -$0.23.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With ATYR analysts setting a high price target of 35.0 and a low target of 9.0, the average target price over the next 12 months is 20.0. Based on these targets, ATYR could surge 872.22% to reach the target high and rise by 150.0% to reach the target low. Reaching the average price target will result in a growth of 455.56% from current levels.
Analysts have provided yearly estimates in a range of -$0.90329 being high and -$0.92337 being low. For ATYR, this leads to a yearly average estimate of -$0.91333. Based on analyst estimates, the high estimate for the next quarter is -$0.23 and the low estimate is -$0.25. The average estimate for the next quarter is thus -$0.24.
